Abbott's XIENCE V Cleared for Treatment of Coronary Artery Disease

 

February 10, 2009

Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference vessel diameter of 2.5 to 4.09 mm.